Publications by authors named "I Marquez-Rodas"

Claim this Profile
A
Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.
Pablo Jara, Marc Ariant, Roberto Jiménez, Marianela Bringas, Blanca Herrero

Breast Cancer Res Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.
Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, Eva Muñoz-Couselo, José Luis Manzano, Miguel-Ángel Berciano-Guerrero

Clin Transl Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801.
Enrique Espinosa, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, Teresa Puértolas, José Luis Manzano

Clin Transl Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
Elisabeth Perez-Ruiz, Luna Minute, Itziar Otano, Maite Alvarez, Maria Carmen Ochoa, Ivan Marquez-Rodas

Nature· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis